Skip to main content
SpringerLink
Log in

Treatment of Patients with Advanced Non-Small Cell Lung Cancer

  • Chapter
Book cover Lung Cancer

Part of the book series: M.D. Anderson Cancer Care Series ((MDCCS))

  • 256 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Readings

  • Albain KS, Crowley JJ, Hutchins L, et al. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer 1993;72:1184–1191.

    CAS  PubMed  Google Scholar 

  • Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618–1626.

    CAS  PubMed  Google Scholar 

  • Alberola V, Camps C, Provencia M, et al. Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer (NSCLC): results of a Spanish Lung Cancer Group phase III trial (GEPC/98-02). Proc Am Soc Clin Oncol 2001;42. Abstract 1229.

    Google Scholar 

  • American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996–3018.

    Google Scholar 

  • Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000;83:447–453.

    Article  CAS  PubMed  Google Scholar 

  • Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol 2000. Abstract 686.

    Google Scholar 

  • Belani CP, Natale RB, Lee JS, et al. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998;39. Abstract 1751.

    Google Scholar 

  • Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602–1613.

    CAS  PubMed  Google Scholar 

  • Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623–631.

    CAS  PubMed  Google Scholar 

  • Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001;19:1734–1742.

    CAS  PubMed  Google Scholar 

  • Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:12–18.

    CAS  PubMed  Google Scholar 

  • Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000;18:1451–1457.

    CAS  PubMed  Google Scholar 

  • Crawford J, O’Rourke M, Schiller JH, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996;14:2774–2784.

    CAS  PubMed  Google Scholar 

  • Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17:3522–3530.

    CAS  PubMed  Google Scholar 

  • Danson A, Clemons M, Middleton M, et al. A randomised study of gemcitabine with carboplatin (GC) versus mitomycin, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). Presentation at the 37th Annual Meeting of the American Society of Clinical Oncology, May 12–15, 2001; San Francisco, CA. Abstract 1285.

    Google Scholar 

  • Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994;5:37–42.

    CAS  PubMed  Google Scholar 

  • Depierre A, Quoix E, Mercier M, et al. Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): a randomized study of vinorelbine (V) versus observation (OB) in patients (Pts) responding to induction therapy (French Cooperative Oncology Group). Proc Am Soc Clin Oncol 2001;42. Abstract 1231.

    Google Scholar 

  • DeVore RF, Fehrenbacher L, Herbst RS, et al. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2001;41. Abstract 1896.

    Google Scholar 

  • Evans TL, Lynch TJ Jr. Lung cancer. Oncologist 2001;6:407–414.

    Article  CAS  PubMed  Google Scholar 

  • Ferry D, Hammond L, Ranson M, et al. Intermittent oral ZD 1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a phase I study. Proc Am Soc Clin Oncol 2000. Abstract 5E.

    Google Scholar 

  • Fossella F. Second-line chemotherapy for non-small cell lung cancer. In: Pass H, Mitchell J, Johnson D, et al, eds. Lung Cancer: Principles and Practice. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:903–909.

    Google Scholar 

  • Fossella F. Docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer (NSCLC): results of a multicenter, randomized phase III study. ECCO—The European Cancer Conference, 2001. Abstract 562 (information from slide presentation).

    Google Scholar 

  • Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354–2362.

    CAS  PubMed  Google Scholar 

  • Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:2529–2536.

    CAS  PubMed  Google Scholar 

  • Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:3390–3399.

    CAS  PubMed  Google Scholar 

  • Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998;16:2133–2141.

    CAS  PubMed  Google Scholar 

  • Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7–33.

    CAS  PubMed  Google Scholar 

  • Gridelli C, Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001;31:277–284.

    Article  CAS  PubMed  Google Scholar 

  • Hensing TA, Socinski MA, Schell MJ, et al. Age does not alter toxicity or survival for patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) treated with carboplatin (C) and paclitaxel (P). Proc Am Soc Clin Oncol 2001;42. Abstract 1382.

    Google Scholar 

  • Jiroutek M, Johnson D, Blum R, et al. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992. Proc Am Soc Clin Oncol 1999;40. Abstract 1774.

    Google Scholar 

  • Johnson DR, DeVore R, Kabbinavar F, et al. Carboplatin (C) + paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc Am Soc Clin Oncol 2001. Abstract 1256.

    Google Scholar 

  • Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001a;19:3210–3218.

    CAS  PubMed  Google Scholar 

  • Kelly K, Giarritta S, Akerley W, et al. Should older patients (Pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001b;42. Abstract 1313.

    Google Scholar 

  • Komiya T, Fukuoka M, Negoro S, et al. Randomized phase III trial compared cisplatin and irinotecan (CPT-P) versus cisplatin and vindesine (VDS-P) versus irinotecan alone (CPT) in patients with advanced non-small cell lung cancer (NSCLC). The final report. Ninth World Conference on Lung Cancer 2000. Abstract 88.

    Google Scholar 

  • Kosmidis PA, Bacoyiannis C, Mylonakis N, et al. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non small cell lung cancer (NSCLC). A preliminary analysis. Proc Am Soc Clin Oncol 2000;41. Abstract 1908.

    Google Scholar 

  • Kunitoh H, Watanabe K, Ohashi Y, et al. Preliminary results of a randomized phase III trial of docetaxel (D) and cisplatin (P) versus vindesine (V) and P in stage IV non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;42. Abstract 1289.

    Google Scholar 

  • Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360–367.

    PubMed  Google Scholar 

  • Le Chevalier T, Brisgand D, Soria JC, et al. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001;6(suppl 1):8–11.

    Article  PubMed  Google Scholar 

  • Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 1997;8:525–529.

    Article  CAS  PubMed  Google Scholar 

  • Martoni A, Guaraldi M, Piana E, et al. Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer. Lung Cancer 1998;22:31–38.

    Article  CAS  PubMed  Google Scholar 

  • Miller VA, Johnson D, Heelan RT, et al. A pilot trial demonstrates the safety of ZD1839 (“Iressa”), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;42. Abstract 1301.

    Google Scholar 

  • Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899–909.

    Google Scholar 

  • Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;42. Abstract 1235.

    Google Scholar 

  • Perng RP, Chen YM, Ming-Liu J, et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997;15:2097–2102.

    CAS  PubMed  Google Scholar 

  • Perrone F, Rossi A, Ianniello GP, et al. Vinorelbine (VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (pts). Results of a phase III randomized trial. Proc Am Soc Clin Oncol 1998;39. Abstract 1752.

    Google Scholar 

  • Peterman AH, Socinski MA, Ribaudo J, et al. Effect of chemotherapy duration (defined vs. continuous) on quality of life in non-small-cell-lung cancer. Proc Am Soc Clin Oncol 2001;42. Abstract 1334.

    Google Scholar 

  • Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1074–1080.

    Article  CAS  PubMed  Google Scholar 

  • Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer—report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633–641.

    CAS  PubMed  Google Scholar 

  • Rodriguez J, Pawel J, Pluzanska A, et al. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;42. Abstract 1252.

    Google Scholar 

  • Rosvold W, Langer CJ, McAleer C, et al. Advancing age does not exacerbate toxicity or compromise outcome in non-small cell lung cancer (NSCLC) patients (pts) receiving paclitaxel-carboplatin (P-C). Proc Am Soc Clin Oncol 1999;40. Abstract 1846.

    Google Scholar 

  • Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145–157.

    Article  CAS  PubMed  Google Scholar 

  • Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122–130.

    CAS  PubMed  Google Scholar 

  • Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;42. Abstract 1227.

    Google Scholar 

  • Schiller JH, Harrington D, Sandler A, et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2000;41. Abstract 2.

    Google Scholar 

  • Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095–2103.

    CAS  PubMed  Google Scholar 

  • Smith IE, O’Brien MER, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:336–1343.

    Google Scholar 

  • Socinski MA, Kies M, Schell MJ, et al. Duration of therapy in stage IIIB/IV non-small cell lung cancer (NSCLC): a multi-institutional phase III trial. Proc Am Soc Clin Oncol 2001;42. Abstract 1232.

    Google Scholar 

  • Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:19–21.

    Article  CAS  PubMed  Google Scholar 

  • Takiguchi Y, Nagao K, Nishiwaki YK, et al. The final results of a randomized phase III trial comparing irinotecan (CPT-11) and cisplatin (CDDP) with vindesine (VDS) and CDDP in advanced non-small-cell lung cancer (NSCLC). Ninth World Conference on Lung Cancer 2000. Abstract 89.

    Google Scholar 

  • Van Meerbeeck JP, Smit EF, Lianes P, et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;42. Abstract 1228.

    Google Scholar 

  • von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000;18:1351–1359.

    Google Scholar 

  • Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459–2465.

    CAS  PubMed  Google Scholar 

  • Yuen A, Halsey J, Fisher G, et al. A Phase I/II trial of ISIS 3521, an antisense inhibitor of pkc-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 2001. Abstract 1234.

    Google Scholar 

Download references

Authors
  1. Ralph Zinner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030-4009, USA

    Frank V. Fossella MD

  2. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030-4009, USA

    Ritsuko Komaki MD

  3. Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030-4009, USA

    Joe B. Putnam Jr. MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Zinner, R. (2003). Treatment of Patients with Advanced Non-Small Cell Lung Cancer. In: Fossella, F.V., Komaki, R., Putnam, J.B. (eds) Lung Cancer. M.D. Anderson Cancer Care Series. Springer, New York, NY. https://doi.org/10.1007/0-387-22652-4_9

Download citation

  • DOI: https://doi.org/10.1007/0-387-22652-4_9

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95507-0

  • Online ISBN: 978-0-387-22652-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation